EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function

Fangkun Luan, Yunqiao Li iD, Jia Ning, Jenny Tuyet Tran, Tanya R Blane, Raag Bhargava, Zhe Huang, Changchun Xiao, David Nemazee iD

Life Science Alliance · 2026

DOI: 10.26508/lsa.202503335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2026. Verfasst von Fangkun Luan und 8 weiteren Autor:innen. Beteiligte Einrichtung: The School of Medicine, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-6, Glycolysis, CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cells are one of the most powerful weapons to fight cancer; however, T-cell exhaustion and dysfunction restrict their long-lasting function in antitumor immunity. B-cell lymphoma 6 (BCL6) has many functions in CD8 T cells; however, it is unclear how it regulates the effector function and exhaustion of CD8 cells. Overall, a low level of BCL6 mRNA in human cancer samples is associated with better outcomes, but high expression of BCL6 is specifically observed in cytotoxic CD8 T cells. We found that BCL6 deficiency in activated CD8 T cells enhanced tumor repression in multiple mouse models. More IL-2–expressing CD8 T cells and reduced proportions of exhausted or dysfunctional CD8 T cells were detected within tumors when Bcl6 was knocked out upon T-cell activation. Glycolysis was promoted, and GLUT3 expression was derepressed in BCL6-deficient CD8 T cells. The BCL6 inhibitor Fx1 promoted antitumor immunity in a T cell–dependent manner. These findings suggest a novel pathway to restore effector function of CD8 T cells by changing their energy use pathways to facilitate long-term tumor resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-bcl-6GlycolysisCD8-Positive T-LymphocytesNeoplasmsAnimalsMiceHumansMice, Inbred C57BLLymphocyte ActivationCell Line, TumorMice, Knockout

Substanzen

Proto-Oncogene Proteins c-bcl-6BCL6 protein, humanBcl6 protein, mouse

Autor:innen und Institutionen

  • The School of Medicine, Nankai University, Tianjin, China.
  • Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Department of Immunology, Suzhou Medical College of Soochow University, Suzhou, China.
  • Molecular and Cell Biology Laboratory, The Salk Institute, La Jolla, CA, USA.
  • Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA nemazee@scripps.edu yunli@scripps.edu cxiao@scripps.edu.

ORCID-Profile: Yunqiao Li, David Nemazee

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Luan, F., Li, Y., Ning, J., Tran, J. T., Blane, T. R., Bhargava, R., Huang, Z., Xiao, C., & Nemazee, D. (2026). Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function. Life Science Alliance. https://doi.org/10.26508/lsa.202503335

Vancouver

Luan F, Li Y, Ning J, Tran JT, Blane TR, Bhargava R, et al. Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function. Life Science Alliance. 2026. doi:10.26508/lsa.202503335

BibTeX
@article{Luan2026,
  author = {Luan, Fangkun and Li, Yunqiao and Ning, Jia and Tran, Jenny Tuyet and Blane, Tanya R and Bhargava, Raag and Huang, Zhe and Xiao, Changchun and Nemazee, David},
  title = {Loss of Bcl6 promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function},
  journal = {Life Science Alliance},
  year = {2026},
  doi = {10.26508/lsa.202503335}
}
Kostenlos starten →